{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '2.3.4.', 'Safety Enppoints', 'The safety endpoints for this study are as follows:', 'incidence of adverse events', 'observed values and changes from baseline in vital signs', \"observed values and change from baseline in the Children's Depression Inventory,\", 'Second Edition (CDI-2), Parent and Self-report Profiles', \"observed values in the Children's Columbia-Suicide Severity Rating Scale (C-SSRS)\", 'observed values in electrocardiogram (ECG) parameters and shifts from screening for', 'clinically significant abnormal findings', 'observed values and changes from screening in clinical laboratory parameters', '(hematology, chemistry, and urinalysis)', '2.3.5.', 'Pharmacokinetic Endpoint', 'The pharmacokinetics of the a- and B-HTBZ metabolites of TEV-50717, and other metabolites', '(as needed), will be explored based on sparse sampling at week 12.', '41']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '3.', 'STUDY DESIGN', '3.1.', 'General Design and Study Schema', '3.1.1.', 'Overall Design and Screening Period', 'This is a Phase 2/3, randomized, double-blind, placebo-controlled, parallel group study in which', 'patients with tics associated with TS will be invited to participate. Patients who qualify for the', 'study will be centrally randomized in a 1:1 ratio (stratified by age at baseline [6 to 11 years, 12 to', '16 years]) to receive either TEV-50717 or placebo. Throughout the study, patients will interact', 'regularly with investigative site personnel, in clinic and by telephone, for the evaluation of', 'safety, tic severity, and behavioral status (in clinic only). The target dose for each patient', 'receiving TEV-50717 will be based on body weight and CYP2D6 impairment status at baseline.', 'Patients will be classified as CYP2D6 impaired if they are receiving a strong CYP2D6 inhibitor', 'or are a CYP2D6 poor metabolizer based on blinded assessment of CYP2D6 genotype at', 'baseline. CYP2D6 status will be used by Interactive Response Technology (IRT) for', 'randomization into the study. The dose of IMP for each patient will be titrated to an optimal level', 'followed by maintenance therapy at that dose. Investigators will be blinded to CYP status, with a', 'dose cap for poor metabolizers prespecified by the IRT (Table 2 2). The overall treatment period', 'will be 12 weeks in duration, including a titration period of 7 weeks, a maintenance period of 5', 'weeks, followed by a washout period of 1 week.', 'For the YGTSS, input from the caregiver/adult is', 'required. For both the TS-PGII and', 'input from the caregiver/adult is permitted. For all', 'other scales, for children 13 years of age and under, interviews may be performed separately or', 'jointly with the caregiver/adult as appropriate or defined by the scale; for children over 13 years', 'of age, caregiver/adult involvement is strongly encouraged. Questions should be directed to the', 'child, but the caregiver/adult should be encouraged to add relevant information. It should be', 'noted that the CDI-2 has individual parent and child questionnaires.', 'Patients who complete the study may be eligible to begin participation in an open-label safety', 'extension study (TV50717-CNS-30047) after the end of the washout period. At the week 13', 'visit, patients may choose to enter Study TV50717-CNS-30047 (on that day), or they will have', 'an additional week to make a decision and return for day 1. Patients not participating in', 'Study TV50717-CNS-30047 will have a follow-up telephone contact to evaluate safety 1 week', 'after the end of the washout period (2 weeks after their last dose of IMP).', '3.1.2.', 'Screening Period', 'The screening period in this study is up to 31 days. After informed consent/assent, depending on', \"the child's age, as appropriate, is obtained, patients who are stable from a medical and\", 'psychiatric standpoint will undergo a screening evaluation, including medical history, physical', 'and neurological examination, laboratory testing, and 12-lead ECG, along with rating scales to', 'assess severity, frequency, and impairment of tics and comorbid TS symptoms and behavioral', 'status.', '42']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'At the discretion of the investigator, the screening visit may be divided into 2 visits if the visit', 'length is felt to be too burdensome for the patient. If the screening visit is divided into 2 visits,', 'the blood sample should be obtained during the first of the 2 visits. Patients who have received', 'comprehensive behavioral intervention for tics (CBIT) for TS or cognitive behavioral therapy', '(CBT) for obsessive-compulsive disorder (OCD) may participate in this study as long as therapy', 'was completed at least 4 weeks prior to screening. Patients will return to the clinic on day 1 to', 'perform baseline procedures and to reconfirm eligibility. Patients may be rescreened 1 time if', 'there is a change in the status of the patient regarding eligibility for the study. (Note: Details of', 'rescreening must be approved and documented by the medical monitor and/or Clinical', 'Surveillance and Training [CST] team.)', '3.1.3.', 'Titration Period', 'During the titration period (7 weeks), patients who remain eligible for participation in the study', 'will be randomized in a 1:1 ratio stratified by age (6 to 11 years, 12 to 16 years) at the baseline', 'visit (day 1), and that evening (ie, after the study visit) will receive 6 mg of blinded IMP with', 'food. Tablets should be taken with food (eg, a snack) and should not be taken on an empty', 'stomach. The titration scheme and maximum dose will be determined by body weight and', 'CYP2D6 impairment status at baseline, as shown in Table 2. Patients and their caregiver/adult', 'will interact weekly with the clinical research staff, either by telephone contact or clinic visit', 'from week 1 through week 7 of the titration period, in order to evaluate safety and establish a', 'dose of IMP that optimally reduces tics and is well tolerated (optimal dose). Safety evaluations', 'during titration include assessment of vital signs, monitoring for adverse events and concomitant', 'medications, 12-lead ECGs, and rating scales for depression and suicidality.', 'In-person (in-clinic) study visits will be scheduled at weeks 2, 4, and 6, and telephone contacts', 'will be scheduled for weeks 1, 3, 5, and 7 in order to assess tic severity and adverse events. The', 'dose of the IMP should be increased on a weekly basis until one of the following criteria is met:', 'The investigator determines that there has been a clinically meaningful reduction in', 'tics, as indicated by a sustained reduction in the TS-CGI', 'The patient experiences a protocol-defined \"clinically significant\" adverse event', '(defined as an adverse event that is related to study medication and is either moderate', 'or severe in intensity or meets the criteria for a serious adverse event).', \"The maximum allowable dose is reached, based on the patient's weight and CYP2D6\", 'impairment status at baseline.', 'Although dose adjustments can be made up to and including the week 7 telephone call, if a stable', 'dose is reached before then, the patient should continue on that dose (ie, the dose should not be', 'increased further) for the remainder of the titration period and throughout maintenance dosing,', 'unless there is a change in symptoms during the titration period. If a patient experiences a', '\"clinically significant\" adverse event attributable to the IMP, the investigator will determine if a', 'dose reduction or suspension is necessary. If the determination that a patient requires a dose', 'reduction or suspension is made during a telephone contact, an unscheduled clinic visit should be', 'conducted as soon as practicable thereafter.', 'Dose adjustments should be made based on all available information, including the patient and', 'caregiver/adult reports of adverse events and tic reduction, the clinical assessment of safety and', '43']\n\n###\n\n", "completion": "END"}